Streetbeat News

Products Services

LTBR

Lightbridge CEO Seth Grae provided an update to shareholders, highlighting 2023 achievements and future milestones. Key developments include strengthening the leadership team, agreements with Centrus Energy for a pilot fuel fabrication facility in Ohio, and an engineering study for CANDU reactors with RATEN ICN. Lightbridge also announced a research study with Texas A&M University, NuScale Power, and Structural Integrity Associates, and a significant finding on plutonium disposition. The company is adopting the Technology Readiness Level (TRL) system, currently at TRL 4-5, indicating progress towards commercialization. Upcoming milestones include expanding the fuel development team, ongoing work at Idaho National Laboratory, completing the CANDU reactor study, the FEED study with Centrus, and commencing manufacturing efforts for irradiation testing. COP28 recognized nuclear energy's role in decarbonization, with a commitment to triple nuclear capacity by 2050, highlighting the demand for Lightbridge's nuclear fuel technology.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:13 pm

DAL

The total solar eclipse on April 8, 2024, will be visible across Mexico, the U.S., and parts of Canada, creating a 'Ring of Fire' effect. Delta Air Lines is offering a special flight for passengers to view the eclipse from the sky. Viewers are advised to use special eclipse glasses or pinhole projectors for safe observation.

Portfolio Pulse from Benzinga Neuro

February 27, 2024 | 1:13 pm

BCOV

Brightcove has announced a strategic partnership with Google Ad Manager to enhance its Ad Monetization service, aiming to help customers monetize their video content more effectively. This collaboration will allow Brightcove to support its customers by providing streamlined ad revenue operations and a seamless ad tech experience, including access to Google's programmatic ad marketplace. The partnership is expected to drive higher CPMs, reduce VAST errors, and offer more competitive rates for Brightcove's customers.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:12 pm

NERV

Minerva Neurosciences received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for Roluperidone, intended for treating negative symptoms in schizophrenia patients. The FDA cited clinical deficiencies including insufficient evidence from a single study, lack of data on concomitant antipsychotic administration, and inadequate long-term safety data at the proposed dose.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:10 pm

WIMI

WiMi Hologram Cloud Inc. (NASDAQ:WIMI), a leading AR technology provider, has developed a hybrid LSTM-ELM model for cryptocurrency market predictions. This model combines machine learning, deep learning, and signal decomposition techniques for improved forecasting accuracy. By analyzing cryptocurrency price data at multiple scales, the model aims to better understand and predict market fluctuations, making it a valuable tool for investors in the volatile cryptocurrency market.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:09 pm

TNXP

Tonix Pharmaceuticals plans to expand the development and partnering of Tonmya in Japan and China for the management of fibromyalgia. The company will file a CTN in Japan and an IND in China, leveraging U.S. Phase 3 data without dosage adjustment. Tonmya's market exclusivity in Asia is supported by issued patents, and a U.S. FDA NDA submission is planned for the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:07 pm

AMRX

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has entered into an exclusive licensing agreement with Zambon Biotech SA for the commercialization of IPX203, a novel Parkinson's disease treatment, in Europe. IPX203 is under review by the U.S. FDA and aims to improve the lives of over 10 million people worldwide with Parkinson's. This agreement is part of Amneal's strategy to make IPX203 available globally, following a similar agreement for Canada and Latin America with Knight Therapeutics Inc.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:06 pm

NDRA

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has installed its first TAEUS liver system in the UK at King's College Hospital NHS Foundation Trust for a clinical study. The study aims to compare the TAEUS technology's liver fat assessment accuracy with MRI. This partnership could potentially expand ENDRA's presence in the UK's NHS network, aligning with its goal to enhance healthcare delivery.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:06 pm

SNAL

Snail, Inc. (NASDAQ:SNAL), a leading developer and publisher of digital entertainment, announced the integration of AI technology into its game development process. This strategic move introduces advancements like text-to-3D model technology and the generation of resources and biomes on a planetary scale, aiming to enhance development efficiency and create more immersive gaming worlds. The company emphasizes a player-first approach, with recent initiatives like Zombie Within and the ARK Survival Ascended's Premium Mods program showcasing their commitment to innovation and community engagement.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm

PTLO

Portillo's has announced plans to open at least nine new restaurants in FY24, with commodity inflation expected to range from 4% to 6%. For 2025, the company targets at least 12% new restaurant growth, with a long-term outlook of approximately 12% to 15% annual new restaurant growth.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm